Given its significant role in various diseases, NICD is considered a potential therapeutic target. Inhibitors of the γ-secretase complex, which prevent the release of NICD, are being investigated as therapeutic agents in cancers where NICD is overactive. Moreover, understanding NICD's mechanisms can aid in developing targeted therapies for other pathological conditions.
